With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...

The researchers treated cancer cells with a combination of venetoclax, a current standard-of-care drug for AML, and a STING ...

Palatin Technologies (PTN) stock gains as the FDA clears a study to test its obesity therapy bremelanotide, with Eli Lillys ...

With the FDA greenlighting its investigational new drug (IND) application, the company is eyeing a mid-2024 timeline to begin ...

The WEHI research team paired venetoclax, a current standard-of-care anti-cancer drug for AML, with a STING agonist, an ...

"The conclusion of enrollment for Regimen G marks a critical step forward for the HEALEY ALS platform Trial," said Drs. Paganoni and Babu. "We extend our thanks to Denali, academic collaborators, and ...

A first-in-class interleukin (IL)-15 receptor agonist, the drug is specifically approved in combination with BCG for adults ...

DD01 is a long-acting dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors. The designation was based on data from a randomized, double-blind, placebo-controlled phase 1 study ...

Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid ...

There are more than 50 glucagon-like peptide-1 receptor agonists (GLP-1RAs) in clinical development for Type 2 diabetes, ...

In the majority of IVF cycles, whether using an agonist or an antagonist protocol, the trigger used is human chorionic gonadotropin (hCG), which shares a common subunit with LH and thus acts as a ...